Understanding factors involved in the regulation of human hematopoiesia requires evaluation of the interaction between relatively homogeneous cell populations and pure growth factors. We are utilizing cell separation procedures to provide methods for obtaining markedly enriched cell populations from marrow wherein heterogeneous cells coexist. We have established in vitro clonogenic assays for detecting proliferation and differentiation of pluripotent (CFU-GEMM), erythroid (BFU-E), and granulocyte-monocyte (CFU-GM) human stem cells. Of particular utility has been the addition of immunologic techniques to separate selectively and recover antigenically defined hematopoietic cells and cells modulating their proliferation and differentiation. We will extend our use of immunologic """"""""panning"""""""" (an antibody-mediated plate-binding technique) in combination with density and adherence separation procedures to provide relatively homogeneous cell populations for generating stimulatory or inhibitory growth substances and to provide target cells for these factors. In addition, the use of purified growth factors will permit more precise delineation of regulatory interactions, particularly those occurring within the marrow hematopoietic microenvironment. We plan specifically to extend our recent studies and investigate several critical biologic variables involved with human hematopoietic regulation: (1) production of stimulatory and inhibitory hematopoietic growth factors by defined immunologic subsets; (2) detection of production and characterization of a differentiation-inducing factor for granulopoiesis (termed GM-CSF-D, differentiation factor-DF, or MGI-2), separate from the previously well-defined proliferation-inducing factor (GM-CSF-P), by use of target cells capable of being induced into differentiating (the human leukemic cell line HL-60); (3) the responsiveness of enriched marrow target cells to a variety of immune system modifiers (e.g., interleukins), other substances, and purified growth factors; and (4) the effects of the """"""""maturation-inducing"""""""" substances, retinoic acid and vitamin D, on altering production of, and responsiveness to, hematopoietic growth factors including stem cell self-replication. These studies will be performed with normal marrow cells to obtain physiologic baseline values and with marrow cells from patients with myeloid leukemia, preleukemia, other myeloproliferative and granulopoietic disorders to assess possible pathophysiological mechanisms in these diseases. (IS)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA036915-03
Application #
3174559
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1984-03-01
Project End
1988-01-31
Budget Start
1986-03-01
Budget End
1988-01-31
Support Year
3
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Neubauer, A; Greenberg, P; Negrin, R et al. (1994) Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 8:638-41
Greenberg, P L (1992) In vitro marrow culture studies in the myelodysplastic syndromes. Semin Oncol 19:34-46
Nagler, A; Binet, C; Mackichan, M L et al. (1990) Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF. Blood 76:1299-307
Lewinsohn, D M; Nagler, A; Ginzton, N et al. (1990) Hematopoietic progenitor cell expression of the H-CAM (CD44) homing-associated adhesion molecule. Blood 75:589-95
Greenberg, P; Negrin, R; Nagler, A et al. (1990) Effects of treatment of myelodysplastic syndromes with recombinant human granulocyte colony stimulating factor. Prog Clin Biol Res 338:151-61
Negrin, R S; Haeuber, D H; Nagler, A et al. (1990) Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36-43
Oksenberg, D; Dieckmann, B S; Greenberg, P L (1990) Functional interactions between colony-stimulating factors and the insulin family hormones for human myeloid leukemic cells. Cancer Res 50:6471-7
Greenberg, P L; Negrin, R; Nagler, A (1990) Effects of CSFs in preleukemia. Bone Marrow Transplant 6 Suppl 1:121-6
Nagler, A; Ginzton, N; Negrin, R et al. (1990) Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes. Leukemia 4:193-202
Greenberg, P; Negrin, R; Nagler, A et al. (1990) Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Int J Cell Cloning 8 Suppl 1:293-300;discussion 300-2

Showing the most recent 10 out of 20 publications